From lab to venture
Does this discovery have the architecture of an investable asset? Start here before the business plan.
Venture design lab →Leonardo Biondi, Biotech Venture Architect: Great science doesn't close rounds or deals.
The architecture beneath it does.
That architecture is the equity story and the strategic case under it: the work that identifies which buyer your science answers, and makes it legible to investors, to pharma, and to the market.
Chief Innovation Officer, IFOM (former)·Lecturer, Università Vita-Salute San Raffaele·Mentor, Seed4Innovation (University of Milan)·Executive education in venture capital, The Wharton School
VENTURE BUILDING
From discovery to deal. Find where you are.
Most scientific discoveries never become companies. Most companies never close a round. Most assets never reach a pharma deal. The gap is always the same: the wrong architecture underneath the story.
Each stage builds the next, but you can enter at any point.
From venture to investable asset
Build the equity story and milestone map before the first investor meeting.
Investor readiness sprint →From story to capital
Pitch deck audit, VC preparation, EIC Accelerator positioning. Close the gap between a good company and a funded one.
Story-first deck rewrite →From asset to pharma deal
Strategic business development for licensing or exit. I bridge the gap between clinical milestones and pharmaceutical boardrooms to secure high-value transactions.
Partnering readiness sprint →Not sure which stage you are at? See the full journey →
Italy Gateway
Italy is not a secondary market. It is the entry point.
Italy's IRCCS network offers a distinctive institutional model: over 50 research hospitals where clinical care and scientific research operate under the same roof, in the disease areas where diagnostics innovation matters most. Structuring the right partnerships within this network is the strategic groundwork that determines whether your European market entry starts strong or stalls. The complexity is real. So is the opportunity.
See the Italy Gateway →Clinical evidence strategy
Italy's IRCCS research hospitals combine clinical care with mandated scientific research. Mapping the right institutional partners, the right disease focus, and the right study design is the strategic work that comes before the regulatory execution.
IRCCS network and clinical partnerships
Not all of the over 50 IRCCS are equivalent. Identifying the institutions with the right research infrastructure, the right investigators, and the right disease focus for your product is a strategic decision that shapes everything downstream.
Market entry architecture
Regulatory pathway, clinical partnerships, regional dynamics, procurement logic: an Italian market entry has moving parts that must be assembled in the right sequence. The strategic architecture comes first. The specialist execution follows.
Leonardo Biondi
Biotech Venture Architect
The fastest way to learn why science fails to get funded is to be there when it does, repeatedly. I have been. You get what I learned, without the years it took.
InsightsAll articles
Worth reading. Worth keeping.
Strategic notes on biotech fundraising and venture design. When there is something worth saying. No filler, no cadence for its own sake. Unsubscribe anytime.
No spam. No cadence for its own sake.
In their words
Heard in the room.
“Leonardo's deep, complementary expertise in life sciences and capital gave my thinking real structure and direction. He helped me see where the real value sat and how to build the infrastructure around it.”
Lili Troshina
Strategy & Growth Leader; Femtech Longevity expert platform founder.
“An exceptionally capable and analytical manager with a deep understanding of the biotech and venture capital industry.”
Jacopo Franchini
Strategic Marketing Advisor, Recordati Rare Diseases.
“Instrumental in refining our long-term strategy. Leonardo transformed my perspective on growth by showing that even the most innovative medical technology needs a robust plan to succeed. His ability to bridge complex science and market viability is rare and invaluable.”
Clarissa Meneghini
Sales Manager for Exoskeletons in Healthcare.
“A fantastic team player and natural leader who bridges science and business in pharma/biotech.”
Francesco Grillo
Start-up & Portfolio Manager, Max Planck Innovation.
The gap between your science and its market will not close itself.
30 minutes. No pitch. An honest conversation about where you are and what the next move is.